The exploding worldwide cancer burden: The impact of cancer on women

International Journal of Gynecological Cancer

Volumn 14, Issue 1, 2004, Pages 1-11

  Wilson, C M ^a   Tobin, S ^a   Young, Robert C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ASIA; AUSTRALIA AND NEW ZEALAND; BREAST CANCER; BREAST EXAMINATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; CONFERENCE PAPER; DEMOGRAPHY; EARLY DIAGNOSIS; EDUCATION PROGRAM; ESOPHAGUS CANCER; EUROPE; FEMALE; GYNECOLOGIC CANCER; HUMAN; KIDNEY CANCER; LARYNX CANCER; LUNG CANCER; MOUTH CANCER; NORTH AMERICA; PANCREAS CANCER; PRIORITY JOURNAL; SMOKING; SOUTH AFRICA; SOUTH AMERICA; STOMACH CANCER; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COST OF ILLNESS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; SMOKING; WOMEN'S HEALTH;

EID: 1442299481     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891x.2004.14178.x     Document Type: Conference Paper

References (59)

1. Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the US Communication from the American Cancer Society, National Cancer Institute and Centers for Disease Control and Prevention. Cancer, 1998;82:1197-207.
2. World Health Organization. World Health report 1998: life in the 21st century, a vision for all. 1998; 1-19. (available from: http://www.who.International/whr2001/2001/archives/1998/index.htm).
3. US Bureau of the Census. Report WP/98, World population profile: 1998. Washington, DC: US Government Printing Office, 1999;55-66.
4. Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of 1.2 major cancers. Bull World Health Organ, 1984;62:163-82.
5. Parkin DM. Global cancer statistics in the year. Erratum in: Lancet Oncol 2001;2:596.
6. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJL. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 BMC Cancer 2002;2:37. (available from: http://www.biomedcentral.com/1471-2407/2/37).
7. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1999 and projected to 2000. Global Burden of Disease and Injury Series, Vol. I. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan Int J Cancer 2001 October 15, 2000;94:153-6.
9. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancerbase, Lyon: IARC Press, 2001.
10. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 2002;288:321-33.
11. Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine-disrupting effects of cigarette smoke and risk of breast cancer. Lancet, 2002;360:1044-9.
12. Thomas DB, Gao DL, Ray RM et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst, 2002;94:1445-57.
13. Pinotti JA, Barros AC, Hegg R, Zeferino LC. Breast cancer control programme in developing countries. Eur J Gynaecol Oncol, 1993;14:355-62.
14. Hoskins WJ, Perez CA, Young RC, eds. Pathogenesis and diagnosis of preinvasive lesions. In: Principles and Practice of Gynecological Oncology, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2000, p 763.
15. Mandelblatt JS, Lawrence WF, Womack SM et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA, 2002;287:2372-89.
16. National Cancer Institute Surveillance Epidemiology and End Results. Mortality: cervix uteri cancer; US mortality age-adjusted rates, total US, 1969-2000. 2003. (available from: http://www.seer.cancer.gov./faststats/html/mor_cervix.html).
17. Health Canada - Sante Canada Population and Public Health Branch. Cervical cancer mortality by province/ territory, 1984-1995. In: Cervical Cancer in Canada 1998. [Cancer updates (serial online)) (available from: http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/updates/cervix-98_e.html).
18. Mandelblatt JS, Lawrence WF, Gaffikin L et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst, 2002;94:1469-83.
19. Ponten J, Adami HO, Bergstrom R et al. Strategies for global control of cervical cancer. Int J Cancer, 1995;63:315-6.
20. Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control, 1992;3:125-36.
21. Royal Thai College of Obstetricians and Gynaecologists (RTCOG), JHPIEGO Corporation Cervical Cancer Prevention Group, Gaffikin L. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet, 2003;361:814-20.
22. Gavarasana S, Kalasapudi RS, Rao TD, Thirumala S. Prevention of carcinoma of cervix with human papillomavirus vaccine. Indian J Cancer, 2000;37:57-66.
23. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 1995;87:796-802.
24. zur Hausen H. Immortalization of human cells and their malignant conversion by high-risk human papillomavirus genotypes. Semin Cancer Biol, 1999;9:405-11.
25. Mantovani F, Banks L. The interaction between p53 and papillomaviruses. Semin Cancer Biol, 1999;9:387-95.
26. Wu L, Goodwin EC, Naeger LK et al. E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression. Mol Cell Biol, 2000;20:7059-67.
27. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16, L1 virus-like particle vaccine. J Natl Cancer Inst, 2001;93:284-92.
28. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 2002;347:1645-51.
29. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med, 1993;328:1365-71 (Erratum in N Engl J Med 1993;329:672).
30. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med, 1993;328:1365-71 (Erratum in N Engl J Med 1993;329:672).
31. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst, 1999;91:434-7.
32. Bingham SA, Day NE, Luben R et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet, 2003;361:1496-501.
33. Makishima M, Lu TT, Xie W et al. Vitamin D receptor as an intestinal bile acid sensor. Science, 2002;296:1313-6.
34. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med, 2003;348:1625-38.
35. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention, etiologic evidence and biological mechanisms. J Nutl, 2002;32:3456S-3464S.
36. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med, 1994;121:241-6.
37. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology, 2003;124:47-56.
38. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med, 1995;333:609-14.
39. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev, 2001;11:535-42.
40. World Health Organization. Confronting the epidemic: a global agenda for tobacco control research. Geneva, Switzerland: Research for International Tobacco Control and The World Health Organization; 1999. (available from: http://www.who.International/toh/TFI/researchritcwho.doc).
41. Jha P, Chaloupka FJ. The economics of global tobacco control. BMJ, 2000;321:358-61.
42. Lee SA, Kang D, Shim KN, Choe JW, Hong WS, Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol, 2003;13:162-8.
43. Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Bhandari P et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess, 2003;7:1-86.
44. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control, 1994;3:242-7.
45. Jha P. The World Bank. International implications of the proposed US legal settlement on tobacco manufacture, production, and marketing. Presentation at the National Cancer Policy Board Tobacco Control Workshop, Washington, DC, July 15, 1997.
46. Chinese Academy of Preventive Medicine. Smoking in China: 1996 national prevalence survey of smoking pattern. Beijing: China Science and Technology Press, 1997. (available from: http://www.jhsph.edu/gtc/survey.pdf).
47. American Lung Association. Fact sheet: international tobacco use. 2003. (available from: http://www.lungusa.org/tobacco/international_factsheet99.html).
48. Kaiserman MJ, Rogers B. Tobacco consumption declining faster in Canada than in the US. Am J Public Health, 1991;81:902-4.
49. Willemsen MC, de Blij B. Tobacco advertising. Tobacco Control. Resource Centre - International Union against Cancer Tobacco Control Factsheets. 2003. (available from: http:factsheets.globalink.org/en/advertising. shtml).
50. Smee C, Parsonage M, Anderson R, Duckworth S. Effect of Tobacco Advertising on Tobacco Consumption: A Discussion Document Reviewing the Evidence. London: Economics & Operational Research Division, Department of Health 1992.
51. Jha P, Chaloupka FJ. Curbing the epidemic: governments and the economics of tobacco control. Washington, DC: World Bank 1999.
52. Bergen AW & Caporaso B. Cigarette smoking. J Natl Cancer Inst, 1999;91:1365-75.
53. Hopkins DP, Briss PA, Ricard CJ et al. The Task Force on Community Preventive Services. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med, 2001;20:10-5.
54. Kmietowicz Z. Tobacco company claims that smokers help the economy. BMJ, 2001;32:126.
55. Max W. The financial impact of smoking on health-related costs: a review of the literature. Am J Health Promot Jun, 2001;15:321-31.
56. Warner KE, Fulton GA, Nicolas P, Grimes DR. Employment implications of declining tobacco product sales for the regional economies of the United States. JAMA, 1996;275:1241-6.
57. Warner KE, Fulton GA. Importance of tobacco to a country's economy: an appraisal of the tobacco industry's economic argument. Tob Control, 1995;4:180-3.
58. Rti International. State cigarette excise taxes: implications for revenue and tax evasion. 2003. (available from: http:// www.rti.org/pubs/8742_Excise_Taxes_FR_5-03.pdf.
59. Murphy JM, Shelley D, Repetto PM, Cummings KM, Mahoney MC. Impact of economic policies on reducing tobacco use among Medicaid clients in New York. Prev Med, 2003;37:68-70.